

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)



(10) International Publication Number
WO 2024/231774 A1

(51) International Patent Classification:

A61K 31/047 (2006.01) A61P 17/00 (2006.01)
A61K 31/132 (2006.01) A61P 25/00 (2006.01)
A61K 31/195 (2006.01) A61P 27/00 (2006.01)
A61K 31/20 (2006.01) A61P 31/00 (2006.01)
A61K 31/201 (2006.01) A61P 35/00 (2006.01)
A61P 39/04 (2006.01) A61P 37/00 (2006.01)
A61P 7/00 (2006.01) A61P 41/00 (2006.01)
A61P 11/00 (2006.01) A61P 43/00 (2006.01)

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2024/054083

(22) International Filing Date:

26 April 2024 (26.04.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1-2023-02967 05 May 2023 (05.05.2023) VN

(72) Inventor; and

(71) Applicant: HUYNH, Cong Nhan [VN/VN]; 166/41 Thich Quang Duc, Ward 4, Phu Nhuan District, Ho Chi Minh City (VN).

(74) Agent: VISION & ASSOCIATES COMPANY LIMITED (VISION & ASSOCIATES); Unit 308-310, 3rd Floor, Hanoi Towers, 49 Hai Ba Trung Street, Hoan Kiem District, Hanoi (VN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: PHARMACEUTICALS CONTAINING CHELATORS WITH STRONG ZN IONS-HOLDING FEATURE FOR THE TREATMENT OF SYMPTOMS AND DISEASES CAUSED BY MICROORGANISMS/DISEASES CAUSED BY TOXINS OR NEUROTOXINS/CANCER/SEVERAL SYNDROMES

(57) Abstract: Metalloproteins on the surface of pathogenic microorganisms have Zn ion-high density, these Zn ions help pathogenic microorganisms to bind to metal ions on metalloproteins on host cell surface (similar to Zn ions find and bind to other metal ions in electric batteries with Zn-other metal electrode pairs). Pathogenic microorganisms and their fragments release Zn-rich products into the host body, these Zn-rich products rapidly make chelators with Zn ions-holding feature (which are mainly derivative of polyamines/aminopolycarboxylic acids) fully hold Zn ions, deplete these active chelators, when active chelators are depleted, Zn-rich products bind to host metalloproteins, generating most symptoms, then host body provide new active chelators which separate Zn-rich products from host metalloproteins, repelling most symptoms. Drugs of invention contains chelators with strong Zn ion-holding feature (which are derivative of polyamines/aminopolycarboxylic acids) that have the following effects: - rapidly reduces most symptoms; - weaken microorganisms and loses their ability to bind to host cells; -strengthen host immune system; - clears the accumulation of Zn-rich products from host metalloproteins, repelling most symptoms; - repelling post-disease syndrome; -and so on. Drugs of invention contains [high active chelators + agent that creates strong physical effects (in treated tissues)] to treat diseased tissues (such as bacterial infection tissues/necrotic tissues/fungal infection tissues/benign tumors/cancerous tumors) with outstanding effectiveness.

WO 2024/231774 A1